Evaluation of Discordance in Differentiated Thyroid Cancer Patients with Negative Radioiodine Scans and Positive Thyroglobulin Values at the Ablation Outcome Control

被引:1
|
作者
Ozkan, Zeynep Gozde [1 ]
Adalet, Isik [1 ]
Turkmen, Cuneyt [1 ]
Issever, Halim [2 ]
Erbil, Yesim [3 ]
Boztepe, Harika [4 ]
Colak, Nese [4 ]
Aral, Ferihan [4 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Nucl Med, Istanbul, Turkey
[2] Istanbul Univ, Istanbul Fac Med, Dept Publ Hlth, Istanbul, Turkey
[3] Istanbul Univ, Istanbul Fac Med, Dept Gen Surg, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Fac Med, Dept Endocrinol & Metab Dis, Istanbul, Turkey
关键词
Differentiated thyroid carcinoma; radioiodine ablation; I-131 whole body scan; lymph node metastases; LYMPH-NODE INVOLVEMENT; NECK DISSECTION; CARCINOMA; PAPILLARY; IMPACT; CONTROVERSIES; METASTASIS; RECURRENCE; AGE;
D O I
10.5152/balkanmedj.2011.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We aimed to evaluate the discordance of 5 mCi (185 MBq) I-131 whole body scan (WBS) and thyroglobulin (Tg) values at the ablation outcome control in differentiated thyroid cancer (DTC) patients who had thyroidectomy and then received radioiodine (RAI) ablation. Materials and Methods: We retrospectively evaluated 36 DTC patients who had RAI treatment in our department between 1992-2009 and whose 5 mCi (185 MBq) I-131 WBS were negative, but Tg values were >= 2 ng/ml during the ablation outcome control (Patient group). Thirty-six patients whose Tg values were < 2 ng/ml and showed no discordance at the same control made up the control group. Patient and control groups were compared in terms of age, gender, histopathological features, ablation dose, Tg value before ablation, and 24. hour RAI uptake value during ablation. The patient group was then evaluated for the cause of the discordance. Results: There were 28 female and 8 male patients whose mean age was 45.6 +/- 11.39 in patient group. In the control group, there were 29 female and 7 male patients whose mean age was 41.5 +/- 11.69. According to the reason of discordance at the ablation outcome control, the patient group was divided into 2 groups: 15 (42%) patients (9 female, 6 male patients, mean age: 50.66 +/- 10.73) who had metastatic lymph nodes as the reason of discordance constituted the lymph node group. The remaining 21 (58%) patients (19 female, 2 male patients, mean age: 41.5 +/- 10.44) were the micrometastatic group in which the cause of discordance could not be determined. There were statistically significant differences in soft tissue invasion (p<0.003), Tg levels before RAI treatment (p<0.002), and diameter of tumor >2 cm (p<0.035) between patient and control groups. Among the patient group, male gender (p<0.03), diameter of tumor >2 cm (p<0.05), thyroid capsule invasion (p<0.0:3), and age>40 (p<0.01) were significantly different between lymph node and micrometastatic groups Conclusion: I-131 WBS/Tg level discordance at the ablation outcome control is mainly caused by metastatic lymph nodes.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 50 条
  • [1] MANAGEMENT OF PATIENTS WITH DIFFERENTIATED THYROID-CANCER WHO HAVE POSITIVE SERUM THYROGLOBULIN LEVELS AND NEGATIVE RADIOIODINE SCANS
    CLARK, OH
    HOELTING, T
    [J]. THYROID, 1994, 4 (04) : 501 - 505
  • [2] Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome
    Trimboli, Pierpaolo
    Zilioli, Valentina
    Imperiali, Mauro
    Giovanella, Luca
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (12) : 1995 - 2001
  • [3] Serum thyroglobulin as a prognostic marker before radioiodine ablation in patients with differentiated thyroid cancer
    Takacsova, E.
    Kralik, R.
    Kausitz, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S542 - S542
  • [4] Thyroglobulin Flare Response After Radioiodine Ablation in 2 Patients With Differentiated Thyroid Cancer
    Tsang, James F.
    Levin, Daniel P.
    Leslie, William D.
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (05) : 421 - 422
  • [5] Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer
    Kebebew, Electron
    Lindsay, Sheila
    Clark, Orlo H.
    Woeber, Kenneth A.
    Hawkins, Randall
    Greenspan, Francis S.
    [J]. THYROID, 2009, 19 (09) : 953 - 956
  • [6] A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
    Kebebew, Electron
    Peng, Miao
    Reiff, Emily
    Treseler, Patrick
    Woeber, Kenneth A.
    Clark, Orlo H.
    Greenspan, Francis S.
    Lindsay, Sheila
    Duh, Quan-Yang
    Morita, Eugene
    [J]. SURGERY, 2006, 140 (06) : 960 - 966
  • [7] Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer:: preliminary results
    Martin, Tomas
    Torres, Alberto
    Cambil, Teresa
    Castro, Juan
    [J]. MEDICINA CLINICA, 2008, 131 (11): : 435 - 435
  • [8] Thyroglobulin-positive, radioiodine-negative thyroid cancer
    Gemsenjäger, E
    [J]. THYROID, 2003, 13 (08) : 833 - 834
  • [9] Thyroglobulin-positive, radioiodine-negative thyroid cancer
    Levy, EG
    [J]. THYROID, 2001, 11 (06) : 599 - 602
  • [10] Pathological evaluation of differentiated thyroid cancer in patients with positive serum thyroglobulin and negative iodine scan
    Ansari, M.
    Babaei, A. A.
    Shafiei, B.
    Javadi, H.
    Assadi, M.
    Nabipour, I.
    Asli, I. N.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (13) : 1925 - 1929